Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes
13 sept. 2022 08h02 HE
|
Novome Biotechnologies, Inc.
- Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease - - Financing includes new investors led by...
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
17 nov. 2021 09h02 HE
|
Novome Biotechnologies, Inc.
- Orally-administered Genetically Engineered Microbial Medicine (GEMM) was safe and well tolerated and demonstrated dose-dependent strain engraftment in healthy volunteers - - Results provide...
Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease
10 nov. 2021 08h32 HE
|
Novome Biotechnologies, Inc.
- Collaboration will leverage Novome’s GEMMs platform for colonizing the human gut with therapeutically engineered bacteria - - Novome to receive $15 million upfront payment; potential to receive up...
Novome Biotechnologies Appoints Bill McLeod as Chief Financial Officer
20 oct. 2021 09h02 HE
|
Novome Biotechnologies, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a clinical-stage biotechnology company developing engineered cellular therapies for the gut, today...
Novome Biotechnologies Initiates Phase 1/2a Study to Evaluate Therapeutically Engineered Bacteria for the Treatment of Enteric Hyperoxaluria
30 juin 2021 09h00 HE
|
Novome Biotechnologies, Inc.
- NOV-001 is the first therapeutically engineered colonizing gut bacteria to be evaluated in humans - - Phase 1 results anticipated in 2021 and Phase 2a preliminary efficacy results in 2022 - SOUTH...
Novome Biotechnologies Appoints Dr. Lachy McLean as Chief Medical Officer
22 juin 2021 08h00 HE
|
Novome Biotechnologies, Inc.
SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today...
Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors
26 mai 2021 10h00 HE
|
Novome Biotechnologies, Inc.
SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced...
Novome Biotechnologies Expands Therapeutic Focus and Platform Capabilities with Acquisition of Preclinical Projects and Intellectual Property from Caribou Biosciences and License to CRISPR-Cas9 Foundational Patent Portfolio
12 août 2020 10h00 HE
|
Novome Biotechnologies, Inc.
− Transfer of Caribou’s novel microbial IP will enable new therapeutic opportunities for Novome − − License to CRISPR-Cas9 intellectual property controlled by Caribou will accelerate the development...
Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer
07 janv. 2020 10h00 HE
|
Novome Technologies, Inc.
− Proceeds to advance lead hyperoxaluria program through Phase 1 clinical proof-of-concept − − Financing led by DCVC Bio and included 5AM Ventures and Alta Partners − SOUTH SAN FRANCISCO, Calif.,...